Systematic Exploration of Privileged Warheads for Covalent Kinase Drug Discovery

Kinase-targeted drug discovery for cancer therapy has advanced significantly in the last three decades. Currently, diverse kinase inhibitors or degraders have been reported, such as allosteric inhibitors, covalent inhibitors, macrocyclic inhibitors, and PROTAC degraders. Out of these, covalent kinas...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Zheng, Bourne, Philip E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695834/
https://www.ncbi.nlm.nih.gov/pubmed/36355497
http://dx.doi.org/10.3390/ph15111322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695834/
https://www.ncbi.nlm.nih.gov/pubmed/36355497
http://dx.doi.org/10.3390/ph15111322

Ejemplares similares